The effects of XAGE1 inhibition were very consistent, not only in melanoma cell lines, but also in cell lines from other tumors, including lung adenocarcinomas and prostate cancer that were shown to present frequent expression of XAGE1 [30, 31]. This evidence concerns the gene XAGE1B and prostate cancer.